Arcturus, a new COVID-19 sub-variant, has caught the attention of the World Health Organization (WHO). The new omicron variant, XBB.1.16, causes familiar symptoms of previous variants of coronavirus.

The Arcturus subvariant stems from the Omicron strain of Covid-19 and is known as XBB.1.16 since it descends from the recombinant variant XBB, which combines two sublineages of Omicron BA.2.

The current spike in COVID-19 cases has been attributed to the spread of a new Covid variant, dubbed Arcturus. The COVID-19 variant, Arcturus, is a sub-variant of Omicron, also known as the XBB.1. ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

Additionally, Arcturus’s robust pipeline, including ARCT-154 for COVID-19, ARCT-810 for OTC deficiency, and ARCT-032 for cystic fibrosis, demonstrates promising risk-adjusted per share values.

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

The Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing ("Rospotrebnadzor") sees a risk of the increased incidence of infections with the Arcturus COVID-19 ...

Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 11.71%, which has investors questioning if this is right ...

Arcturus Therapeutics Holdings Inc. (the ... LUNAR and STARR technologies have been established through multiple COVID-19 and seasonal influenza vaccine trials, which included more than 20,000 ...

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154 ...